Merck teams with Affimed on immuno-oncology combo

Germany's Affimed has inked a deal that makes it the latest in a long string of biotechs to partner up with Merck ($MRK) on a combination study using the PD-1 blockbuster Keytruda. Affimed is underwriting a Phase Ib study that combined its drug AFM13 with Keytruda against Hodgkin lymphoma. AFM13 is a bispecific antibody that is designed to engage NK (natural killer) cells. And Affimed has rights to spring forward into Phase III, if the data look right. Release

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.